Fidasimtamab, also known as DLTV – 1504, represents the novel strategy in the battle against multiple myeloma. This therapy a dual-specific agent designed to simultaneously engage CD3-positive immune https://fidasimtamabbh2950928108.aboutyoublog.com/55185038/fidasimtamab-this-emerging-hope-in-multiple-plasma-cell-management